Liquidia Corporation is set to proceed with the commercial launch of its inhalation powder, YUTREPIA, following a legal victory against United Therapeutics. On May 30, 2025, the U.S. District Court for the Middle District of North Carolina denied United Therapeutics' request for a preliminary injunction and a temporary restraining order. United Therapeutics had sought to block Liquidia from commercializing YUTREPIA, alleging infringement of their patent. The court's decision was influenced by the conclusion that United Therapeutics is unlikely to succeed on the merits of its claims. With the denial of this request, Liquidia is clear to begin shipping YUTREPIA to specialty pharmacies, just days after receiving FDA approval for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.